TransMedics Group, Inc. (TMDX)
NASDAQ: TMDX · Real-Time Price · USD
75.48
+2.57 (3.52%)
At close: Jun 15, 2026, 4:00 PM EDT
75.08
-0.40 (-0.53%)
After-hours: Jun 15, 2026, 7:55 PM EDT
TransMedics Group Revenue
TransMedics Group had revenue of $173.93M in the quarter ending March 31, 2026, with 21.18% growth. This brings the company's revenue in the last twelve months to $635.89M, up 30.24% year-over-year. In the year 2025, TransMedics Group had annual revenue of $605.49M with 37.13% growth.
Revenue (ttm)
$635.89M
Revenue Growth
+30.24%
P/S Ratio
4.08
Revenue / Employee
$708,118
Employees
898
Market Cap
2.61B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 605.49M | 163.95M | 37.13% |
| Dec 31, 2024 | 441.54M | 199.92M | 82.74% |
| Dec 31, 2023 | 241.62M | 148.16M | 158.53% |
| Dec 31, 2022 | 93.46M | 63.20M | 208.83% |
| Dec 31, 2021 | 30.26M | 4.62M | 18.03% |
| Dec 31, 2020 | 25.64M | 2.04M | 8.62% |
| Dec 28, 2019 | 23.60M | 10.59M | 81.33% |
| Dec 31, 2018 | 13.02M | 5.33M | 69.38% |
| Dec 30, 2017 | 7.69M | -5.33M | -40.96% |
| Dec 31, 2016 | 13.02M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Integer Holdings | 1.86B |
| LivaNova | 1.43B |
| Haemonetics | 1.33B |
| Neogen | 870.56M |
| iRhythm Holdings | 787.85M |
| NovoCure | 674.41M |
| UFP Technologies | 608.85M |
| PROCEPT BioRobotics | 322.02M |
TMDX News
- 3 days ago - Johnson Fistel Investigates TransMedics Group, Inc. (TMDX) After Recent Disclosures Concerning Margin Pressure and NOP Investments - GlobeNewsWire
- 13 days ago - TransMedics Group Transcript: 46th Annual William Blair Growth Stock Conference - Transcripts
- 20 days ago - TransMedics price target lowered to $75 from $85 at Stifel - TheFly
- 25 days ago - TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - PRNewsWire
- 27 days ago - TransMedics to Present at the William Blair 46th Annual Growth Stock Conference - PRNewsWire
- 5 weeks ago - TransMedics Group Proxy statement: Proxy filing - Filings
- 5 weeks ago - TransMedics downgraded to Perform from Outperform at Oppenheimer - TheFly
- 5 weeks ago - TransMedics price target lowered to $140 from $157 at Baird - TheFly